Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
REGULATORY
Japan Puts a Hold on Coverage Discussions for Elevidys over Safety Concerns
Japan’s key reimbursement policy panel on June 18 agreed to temporarily pause its discussions on insurance coverage for Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) treatment Elevidys (delandistrogene moxeparvovec). The decision follows cases of fatal acute liver failure (ALF) reported overseas…
To read the full story
Related Article
REGULATORY
- 16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
July 10, 2025
- Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
- Janssen’s Balversa Gets Green Light for NHI Listing
July 10, 2025
- Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
- Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
July 10, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…